Ladenburg Thalmann Initiates Coverage On Biodexa Pharmaceuticals with Buy Rating, Announces Price Target of $8
Portfolio Pulse from Benzinga Newsdesk
Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Biodexa Pharmaceuticals (BDRX) with a Buy rating and a price target of $8.
February 08, 2024 | 5:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ladenburg Thalmann initiated coverage on Biodexa Pharmaceuticals with a Buy rating and a price target of $8.
The initiation of coverage by a reputable analyst with a Buy rating and a specific price target usually signals a positive outlook on the stock, potentially leading to increased investor interest and a positive short-term price movement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100